Treatments that target a fragment of the mutant protein that causes Huntington's disease might be more effective than treatments—now in clinical trials—that target the whole protein but leave this ...

Neurocrine Biosciences has rebounded 60% since April 2025, driven by robust Ingrezza sales and Crenessity's uncontested launch. Read why NBIX stock is a hold.

The worlds of professional sports and entrepreneurship are colliding this summer in Park City, Utah, where elite NFL athletes will meet with proven operators and vetted founders for three days of deal ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...